Lung Cancer Trial, By Invitation (NCT06730477)

Lung Cancer Trial, By Invitation NCT06730477 Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06730477 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

A diagnosis of lung adenocarcinoma (a specific type of lung cancer) confirmed through laboratory tissue testing.
No other type of cancer or tumour is present alongside the lung adenocarcinoma.
A specific genetic change in the EGFR gene has been identified — either a deletion in a region called Exon 19, or a mutation called L858R, or one of these combined with changes at other locations (confirm with trial site).
First-line treatment (the first course of treatment received for this condition) involves targeted therapy, with or without chemotherapy.
Aged 18 to 80 years old.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

A history of other cancers or malignant tumours.
Treatment that has been irregular or where the person has not followed the prescribed plan consistently.
Medical records that are incomplete, or cases where the person has been lost to follow-up (meaning contact was not maintained during a previous treatment or study).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 30 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06730477

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase: Not Applicable

Status: By Invitation

Condition: Lung Cancer

More information: https://clinicaltrials.gov/study/NCT06730477

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who may be able to join

A diagnosis of lung adenocarcinoma (a specific type of lung cancer) confirmed through laboratory tissue testing.
No other type of cancer or tumour is present alongside the lung adenocarcinoma.
A specific genetic change in the EGFR gene has been identified — either a deletion in a region called Exon 19, or a mutation called L858R, or one of these combined with changes at other locations (confirm with trial site).
First-line treatment (the first course of treatment received for this condition) involves targeted therapy, with or without chemotherapy.
Aged 18 to 80 years old.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

A history of other cancers or malignant tumours.
Treatment that has been irregular or where the person has not followed the prescribed plan consistently.
Medical records that are incomplete, or cases where the person has been lost to follow-up (meaning contact was not maintained during a previous treatment or study).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 30 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

By Invitation

Phase

Not Applicable

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Registry

ClinicalTrials.gov

Start date

1 January 2021

Est. completion

30 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

progression-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov

Who may and may not be able to join

Who may be able to join

Who may not be able to join

GP referral letter

Who may be able to join

Who may not be able to join

Trial details

Where this trial is recruiting

Primary endpoints

Can't join this trial?

Expanded access pathways

Other trials for Lung Cancer